The U.S. Federal Circuit recently clarified the standard that patent challengers must satisfy when attempting to invalidate patented inventions directed to new uses for known drugs. Although designated as a nonprecedential...more
1/3/2018
/ Appeals ,
Clear and Convincing Evidence ,
Hatch-Waxman ,
Obviousness ,
Patent Invalidity ,
Patents ,
Pharmaceutical Patents ,
Prescription Drugs ,
Prior Art ,
Section 103 ,
Standard of Review